Remy B Verheijen Selected Research

1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazine

1/2021	Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C.
1/2021	Parent and Metabolite Concentration-QT Modeling to Evaluate QT-Interval Prolongation at Savolitinib Therapeutic Doses.
1/2021	A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
1/2020	Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
1/2020	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Remy B Verheijen Research Topics

Disease

12	Neoplasms (Cancer) 01/2022 - 04/2014
7	Sarcoma (Soft Tissue Sarcoma) 11/2021 - 01/2016
6	Renal Cell Carcinoma (Grawitz Tumor) 01/2020 - 01/2016
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2020
3	Disease Progression 01/2022 - 01/2020
2	Vomiting 01/2021 - 01/2019
2	Nausea 01/2021 - 01/2019
2	Breast Neoplasms (Breast Cancer) 01/2018 - 01/2017
1	Stomatitis 01/2022
1	Chemical and Drug Induced Liver Injury 01/2021
1	Anaphylaxis (Anaphylactic Shock) 10/2020
1	Hypersensitivity (Allergy) 10/2020
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Acute Kidney Injury (Acute Renal Failure) 01/2020
1	Fatigue 01/2019
1	Edema (Dropsy) 01/2019
1	Diarrhea 01/2019
1	Hematologic Neoplasms (Hematological Malignancy) 01/2019
1	Proteinuria 01/2019
1	Kidney Neoplasms (Kidney Cancer) 01/2018
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2018
1	Hypertension (High Blood Pressure) 01/2017

Drug/Important Bio-Agent (IBA)

7	pazopanib FDA Link 11/2021 - 01/2016
5	Tyrosine Kinase InhibitorsIBA 01/2021 - 12/2016
5	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA 01/2021 - 01/2020
3	Pharmaceutical PreparationsIBA 10/2020 - 01/2017
2	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2021
2	Everolimus FDA Link 01/2022 - 01/2018
2	osimertinibIBA 01/2021 - 01/2020
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 01/2021
2	Focal Adhesion Protein-Tyrosine KinasesIBA 01/2019 - 01/2019
2	ElacridarIBA 01/2018 - 01/2017
1	Circulating Tumor DNAIBA 01/2022
1	Gefitinib (Iressa)FDA Link 01/2021
1	Alanine Transaminase (SGPT)IBA 01/2021
1	Investigational DrugsIBA 10/2020
1	Sunitinib (Sutent)FDA Link 01/2020
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018
1	Angiogenesis InhibitorsIBA 01/2018
1	TOR Serine-Threonine KinasesIBA 01/2018
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2017
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2017
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2017
1	Glycoproteins (Glycoprotein)IBA 01/2017
1	PRS-110IBA 04/2014
1	Dihydrotachysterol (AT 10)IBA 04/2014

Therapy/Procedure

2	Therapeutics 01/2021 - 03/2019
1	Radiotherapy 11/2021